Key result
UACDT increases 12-month vein segment patency by ~133% compared to standard treatment.
Why the study?
Does ultrasound-accelerated catheter-directed thrombolysis improve patency and reduce reflux compared to standard treatment in patients with first iliofemoral deep vein thrombosis?
RCT
Single-blind
randomized
Yes
Does ultrasound-accelerated catheter-directed thrombolysis improve patency and reduce reflux compared to standard treatment in patients with first iliofemoral deep vein thrombosis?
Answers are grounded in this paper and cite their sources.
Ultrasound-accelerated catheter-directed thrombolysis improves long-term vein patency and reduces popliteal reflux, which are independently associated with a lower risk of moderate-to-severe postthrombotic syndrome.
BACKGROUND: Adjunctive catheter-directed thrombolysis shows variable efficacy in preventing postthrombotic syndrome (PTS), despite restored patency. OBJECTIVES: This Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome (CAVA) trial subanalysis investigated the effect of ultrasound-accelerated catheter-directed thrombolysis (UACDT) on patency, reflux, and their relevance in PTS development. METHODS: This multicenter, randomized, single-blind trial enrolled patients (aged 18-85 years) with a first iliofemoral deep vein thrombosis and symptom duration ≤14 days. Patency and reflux were assessed by duplex ultrasound at 12 months (T12) and long-term (LT) follow-up (median, 39.5 months; IQR, 24.0-63.0 months). PTS was diagnosed using the Villalta score. RESULTS: UACDT significantly improved patency in all vein segments at T12 (60.3% UACDT vs 25.9% standard treatment [ST]; P = .002) and LT (45.2% UACDT vs 11.9% ST; P < .001). Popliteal patency, however, was similar between groups (87.9% UACDT vs 83.3% ST; P = .487). Reflux was similar between groups at T12 and LT; only popliteal reflux was significantly reduced in the UACDT group at LT (22.6% UACDT vs 44.8% ST; P = .010). Absent iliac patency at T12 was associated with increased PTS risk in the ST group only (odds ratio [OR], 10.84; 95% CI, 1.93-60.78; P = .007). In the UACDT group, popliteal reflux at T12 was associated with moderate-to-severe PTS at T12 (OR, 4.88; 95% CI, 1.10-21.57; P = .041) and LT (OR, 5.83; 95% CI, 1.44-23.63; P = .009). Combined popliteal reflux and absent iliac patency significantly amplified PTS risk (OR, 10.79; 95% CI, 2.41-48.42; P < .001). CONCLUSION: UACDT improved patency and reduced popliteal reflux. Iliac patency and popliteal reflux are independently associated with moderate-to-severe PTS and contribute synergistically to its development. However, a proportion of moderate-to-severe PTS cases lacks an evident underlying cause.
No takes yet. Share an insight, caveat, or question.
Hupperetz et al. (2024) conducted an RCT in first iliofemoral deep vein thrombosis. Ultrasound-accelerated catheter-directed thrombolysis (UACDT) vs. Standard treatment (anticoagulation) was evaluated on Patency in all vein segments at 12 months (p=.002). Ultrasound-accelerated catheter-directed thrombolysis improved patency in all vein segments at 12 months compared to standard treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: